Across TCGA pan-cancer cohorts, CARD11 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CARD11 data layer compared with 26 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CARD11 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CARD11 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, GBM, and PDAC are the cancer types where CARD11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	1.000	0.872	.009	15	view →
GBM	OS	Median	All	0.453	0.634	.028	3	view →
PDAC	OS	Tertile	IV	0.395	0.934	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: CARD11 tumor-vs-normal RNA expression · all CARD11 data types